Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 156

1.

Risk assessment of drug-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a disproportionality analysis using the French Pharmacovigilance Database.

Agier MS, Boivin N, Maruani A, Giraudeau B, Gouraud A, Haramburu F, Jean Pastor MJ, Machet L, Jonville-Bera AP.

Br J Dermatol. 2016 Nov;175(5):1067-1069. doi: 10.1111/bjd.14649. Epub 2016 Aug 11. No abstract available.

PMID:
27060861
2.

Which psychoactive substances are used by patients seen in the healthcare system in French overseas territories? Results of the OPPIDUM survey.

Daveluy A, Frauger E, Peyrière H, Moracchini C, Haramburu F, Micallef J.

Fundam Clin Pharmacol. 2017 Feb;31(1):126-131. doi: 10.1111/fcp.12233. Epub 2016 Oct 5.

PMID:
27581837
3.

Acute Methiopropamine Intoxication After "Synthacaine" Consumption.

Daveluy A, Castaing N, Cherifi H, Richeval C, Humbert L, Faure I, Labadie M, Allorge D, Haramburu F, Molimard M, Titier K.

J Anal Toxicol. 2016 Nov;40(9):758-760. Epub 2016 Jul 29.

PMID:
27474360
4.

Causality assessment in pharmacovigilance: The French method and its successive updates.

Miremont-Salamé G, Théophile H, Haramburu F, Bégaud B.

Therapie. 2016 Apr;71(2):179-86. doi: 10.1016/j.therap.2016.02.010. Epub 2016 Feb 6. English, French.

PMID:
27080836
5.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study..

Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.

PMID:
26762990
6.

Illicit drugs or medicines taken by parachuting.

Daveluy A, Géniaux H, Eiden C, Boucher A, Chenaf C, Deheul S, Spadari M, Gérardin M, Miremont-Salamé G, Haramburu F; French Network of Addictovigilance Centres..

Fundam Clin Pharmacol. 2016 Apr;30(2):185-90. doi: 10.1111/fcp.12172. Epub 2015 Dec 23.

PMID:
26609911
7.

Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients.

Duffau P, Wittkop L, Lazaro E, le Marec F, Cognet C, Blanco P, Moreau JF, Dauchy FA, Cazanave C, Vandenhende MA, Bonnet F, Thiebaut R, Pellegrin I; ANRS CO3 Aquitaine Cohort Study Group..

AIDS. 2015 Oct 23;29(16):2099-108. doi: 10.1097/QAD.0000000000000807.

PMID:
26544576
8.

Validation and Reproducibility of the Updated French Causality Assessment Method: an Evaluation by Pharmacovigilance Centres & Pharmaceutical Companies.

Théophile H, Dutertre JP, Gérardin M, Valnet-Rabier MB, Bidault I, Guy C, Haramburu F, Hillaire-Buys D, Méglio C, Arimone Y.

Therapie. 2015 Sep-Oct;70(5):465-76. doi: 10.2515/therapie/2015028. Epub 2015 Jun 26.

PMID:
26423144
9.

Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study.

Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group..

HIV Med. 2016 Apr;17(4):255-68. doi: 10.1111/hiv.12294. Epub 2015 Jul 28.

PMID:
26216031
10.

Signal identification in addictovigilance: the functioning of the French system.

Jouanjus E, Gibaja V, Kahn JP, Haramburu F, Daveluy A.

Therapie. 2015 Mar-Apr;70(2):113-31. doi: 10.2515/therapie/2015011. Epub 2015 Apr 9. English, French.

11.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group.; Royal Free Hospital Clinic Cohort.; INSIGHT study group.; SMART study group.; ESPRIT study group..

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

12.

Statins in pregnancy: new safety data are reassuring, but suspension of treatment is still advisable.

Haramburu F, Daveluy A, Miremont-Salamé G.

BMJ. 2015 Mar 17;350:h1484. doi: 10.1136/bmj.h1484. No abstract available.

PMID:
25784692
13.

Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.

Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group..

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523.

PMID:
25763785
14.

Preventability of adverse effects of analgesics: analysis of spontaneous reports.

Cazacu I, Miremont-Salamé G, Mogosan C, Fourrier-Réglat A, Loghin F, Haramburu F.

Eur J Clin Pharmacol. 2015 May;71(5):625-9. doi: 10.1007/s00228-015-1829-8. Epub 2015 Mar 5.

PMID:
25736702
15.

Drugs and Sleep Apneas? A review of the French Pharmacovigilance database.

Linselle M, Montastruc F, Jantzen H, Valnet-Rabier MB, Haramburu F, Coquerel A, Gouraud A, Perault-Pochat MC, Bagheri H, Montastruc JL.

Therapie. 2015 Jul-Aug;70(4):347-50. doi: 10.2515/therapie/2014218. Epub 2015 Feb 16.

PMID:
25679185
16.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration., Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

17.

Probable interaction between an oral vitamin K antagonist and turmeric (Curcuma longa).

Daveluy A, Géniaux H, Thibaud L, Mallaret M, Miremont-Salamé G, Haramburu F.

Therapie. 2014 Nov-Dec;69(6):519-20. doi: 10.2515/therapie/2014062. Epub 2014 Sep 18.

PMID:
25230280
18.

Severe morbidity according to sex in the era of combined antiretroviral therapy: the ANRS CO3 Aquitaine Cohort.

Hessamfar M, Colin C, Bruyand M, Decoin M, Bonnet F, Mercié P, Neau D, Cazanave C, Pellegrin JL, Dabis F, Morlat P, Chêne G; GECSA study group..

PLoS One. 2014 Jul 30;9(7):e102671. doi: 10.1371/journal.pone.0102671. eCollection 2014.

19.

Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group..

Lancet. 2014 Jul 19;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8.

PMID:
25042234
20.

Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study.

Bénard-Laribière A, Miremont-Salamé G, Pérault-Pochat MC, Noize P, Haramburu F; EMIR Study Group on behalf of the French network of pharmacovigilance centres..

Fundam Clin Pharmacol. 2015 Feb;29(1):106-11. doi: 10.1111/fcp.12088. Epub 2014 Sep 25.

PMID:
24990220

Supplemental Content

Loading ...
Support Center